HSBC Bank Plc : Form 8 (DD) - Minco Plc Ap19 FORM 8.3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
20
HSBC Bank Plc : Form 8 (DD) - Minco Plc

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

  1. KEY INFORMATION
Name of person dealing (Note 1) HSBC Bank Plc
Company dealt in Minco Plc
Class of relevant security to which the dealings being disclosed relate (Note 2) Ordinary Shares
Date of dealing 19th June 2017
  1. INTERESTS AND SHORT POSITIONS  
  2.         Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
  Long Short
  Number   (%) Number   (%)
(1) Relevant securities 5,253,000  1.098%  
(2) Derivatives (other than options)   5,253,000  1.098%
(3) Options and agreements to purchase/sell    
Total 5,253,000  1.098% 5,253,000  1.098%
       
  1.         Interests andshortpositionsinrelevantsecuritiesofthe company, otherthanthe class dealt in (Note 3)
Class of relevant security: Long Short
  Number   (%) Number   (%)
(1) Relevant securities    
  (2) Derivatives (other than options)    
  (3) Options and agreements to purchase/sell    
Total    
       

Ap20

  1. DEALINGS (Note 4)

(a)      Purchases andsales

  Purchase/sale   Number of relevant securities   Price per unit (Note 5)
Purchase 400,000 2.40  p
Sale 400,000 2.40 p

(b)      Derivatives transactions(otherthanoptionstransactions)

Product name, e.g. CFD Nature of transaction (Note 6) Number of relevant securities (Note 7) Price per unit (Note 5)
       

(c)      Options transactionsinrespectofexistingrelevantsecurities

(i)       Writing, selling, purchasingorvarying

Product name, e.g. call option Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)
             

(ii)      Exercising

Product name, e.g. call option Number of securities Exercise price per unit (Note 5)
     

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8) Details Price per unit (if applicable) (Note 5)
     

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full detailsofanyagreement,arrangementorunderstandingbetweenthepersondisclosing andanyotherpersonrelatingtothevotingrightsofanyrelevantsecuritiesunderanyoption referred to on this form or relating to the voting rights or future acquisition or disposal of any relevantsecuritiestowhichanyderivativereferredtoonthisformisreferenced.Ifnone, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            NO

Date of disclosure 20-June-2017
Contact name Shwetha BR
Telephone number +44 20 7088 2000
If a connected EFM, name of offeree/offeror with which connected NA
If a connected EFM, state nature of connection (Note 10) NA
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DAN, GPRO, PSNL Deals Under Investor Scrutiny

Updated Category News Views 40

Behind the Curtain: What Do These Deals Mean for Shareholders? Sometimes, investing in a stock ain't just about numbers on a screen—it's about untangling the whole messy ball of yarn these companies hand you with a smile. We're looking at Dana Incorporated (NYSE: DAN), GoPro, Inc. (NASDAQ: GPRO), and Personalis, Inc. (NASDAQ: PSNL). They've all got deals on the table,...

Continue Reading
Raytron Dominates Global Thermal Imaging Market in 2026

Updated Category News Views 106

Raytron's Market Supremacy: By the Numbers If you're looking at the thermal imaging sector and wondering what's what, take a clue from Raytron. This outfit isn't just playing the game—it's running the show with a staggering 30% of the global market in 2025. That's right, they hold the medal for leading global shipments in thermal imaging, and unlike many industries...

Continue Reading
Asphalt Additives Market Set for $7.07B Boom by 2031

Updated Category News Views 65

Asphalt Additives: A Lucrative Growth Path Let me tell you, the asphalt additives market isn't just sticking to the roads; it's rolling out real potential. Heading for a $7.07B finish line by 2031 with a steady pace of 7.3% CAGR, it's a road worth staking your claims on. The underlying story? It's more than just laying tar. Pavement to Profit: Key Drivers The asphalt...

Continue Reading
Pearl Meyer Leaders Grab NACD's Coveted Governance Honor

Updated Category News Views 26

NACD Recognition for Governance Grit Some folks just know how to steer a ship, and that's exactly what Pearl Meyer's Matt Turner and Jannice Koors have been doing. This year, they made it onto the NACD's 2026 Directorship 100 list, swinging as heavy hitters in the Governance Professionals category. It's not just another day at the office when you're honored by the...

Continue Reading
Epson Unveils Early Black Friday Tech Deals

Updated Category News Views 69

Diving Headfirst into Holiday Tech Splurging The holiday hustle is upon us, folks, and Epson's stepping up with early Black Friday deals that'll have tech heads scrambling. They’re cutting prices up to $250 on their swanky home lineup—projectors, printers, scanners, you name it. This ain't just about making someone else smile, though; it's about the sweet spot where...

Continue Reading
Doximity's Legal Woes: Class Action Deadline Looms

Updated Category News Views 15

The Truth Behind Doximity's Promises The brass tacks of investing often boil down to trust—a commodity that's now in short supply over at Doximity, Inc. (NYSE: DOCS). Investors have been left hanging after promises of lucrative engagement signals turned out to be a mere pipe dream. Levi & Korsinsky, LLP sounds the alarm on what's shaping up to be a high-stakes class...

Continue Reading
Insulin Delivery Devices: A Billion-Dollar Surge

Updated Category News Views 20

When's the last time you saw a medical device market promising a $10 billion leap in under five years? Yeah, the insulin delivery devices market's got that kind of upside, projected to skyrocket from $16.92 billion in 2026 to a whopping $26.37 billion by 2031. That's a 9.3% annual growth rate. The numbers and the stakes are both staggering. Regional and Segment Leaders...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Terra-Gen's $950M Lockhart Facility Powers California

Updated Category News Views 128

A New Giant in California's Solar Landscape Out in California's desert, Terra-Gen has flipped the switch on something pretty colossal: the $950 million Lockhart Solar and Storage Project. Picture this—a solar beast boasting 538.7 MW of capacity, primed to light up around 350,000 homes and businesses. That's not just flipping a light switch; that's sparking a fire that...

Continue Reading
Defense Contractors Push Forward Amid Indictments

Updated Category News Views 18

The Big Names Hold Steady Defense contractors are showing off their shiny earnings just as some disturbing headlines shake things up. It's like they're putting their best foot forward to steady the ship while the waters get choppy with terrorism charges and all sorts of geopolitical noise. Follow the smart money to see where the true bets are being placed—it all unfolds...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading